Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 290

1.

Factors Predictive of Remission of Chronic Anterior Uveitis.

Sobrin L, Pistilli M, Dreger K, Kothari S, Khachatryan N, Artornsombudh P, Pujari SS, Foster CS, Jabs DA, Nussenblatt RB, Rosenbaum JT, Levy-Clarke GA, Sen HN, Suhler EB, Thorne JE, Bhatt NP, Kempen JH; Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study Research Group.

Ophthalmology. 2019 Nov 28. pii: S0161-6420(19)32301-2. doi: 10.1016/j.ophtha.2019.11.020. [Epub ahead of print]

PMID:
31932091
2.

Standardization of Nomenclature for Ocular Tuberculosis - Results of Collaborative Ocular Tuberculosis Study (COTS) Workshop.

Agrawal R, Agarwal A, Jabs DA, Kee A, Testi I, Mahajan S, McCluskey PJ, Gupta A, Palestine A, Denniston A, Banker A, Invernizzi A, Fonollosa A, Sharma A, Kumar A, Curi A, Okada A, Schlaen A, Heiligenhaus A, Kumar A, Gurbaxani A, Bodaghi B, Islam Shah B, Lowder C, Tappeiner C, Muccioli C, Vasconcelos-Santos DV, Goldstein D, Behra D, Das D, Makhoul D, Baglivo E, Denisova E, Miserocchi E, Carreno E, Asyari F, Pichi F, Sen HN, Uy H, Nascimento H, Tugal-Tutkun I, Arevalo JF, Davis J, Thorne J, Hisae Yamamoto J, Smith J, Garweg JG, Biswas J, Babu K, Aggarwal K, Cimino L, Kuffova L, Agarwal M, Zierhut M, Agarwal M, De Smet M, Tognon MS, Errera MH, Munk M, Westcott M, Soheilian M, Accorinti M, Khairallah M, Nguyen M, Kon OM, Mahendradas P, Yang P, Neri P, Ozdal P, Amer R, Lee R, Distia Nora R, Chhabra R, Belfort R, Mehta S, Shoughy S, Luthra S, Mohamed SO, Chee SP, Basu S, Teoh S, Ganesh S, Barisani-Asenbauer T, Guex-Crosier Y, Ozyazgan Y, Akova Y, Habot-Wilner Z, Kempen J, Nguyen QD, Pavesio C, Gupta V; Collaborative Ocular Tuberculosis Study (COTS) Group.

Ocul Immunol Inflamm. 2019 Dec 10:1-11. doi: 10.1080/09273948.2019.1653933. [Epub ahead of print]

PMID:
31821096
3.

Visual Acuity Outcome over Time in Non-Infectious Uveitis.

Pistilli M, Joffe MM, Gangaputra SS, Pujari SS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Sen HN, Suhler EB, Thorne JE, Bhatt NP, Foster CS, Begum H, Fitzgerald TD, Dreger KA, Altaweel MM, Holbrook JT, Kempen JH; Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group.

Ocul Immunol Inflamm. 2019 Dec 10:1-8. doi: 10.1080/09273948.2019.1687733. [Epub ahead of print]

PMID:
31821051
4.

Antimetabolite Therapy for Uveitis: Methotrexate or Mycophenolate?

Jabs DA.

JAMA Ophthalmol. 2019 Sep 10. doi: 10.1001/jamaophthalmol.2019.3964. [Epub ahead of print] No abstract available.

PMID:
31503274
5.

Comparison Between Methotrexate and Mycophenolate Mofetil Monotherapy for the Control of Noninfectious Ocular Inflammatory Diseases.

Gangaputra SS, Newcomb CW, Joffe MM, Dreger K, Begum H, Artornsombudh P, Pujari SS, Daniel E, Sen HN, Suhler EB, Thorne JE, Bhatt NP, Foster CS, Jabs DA, Nussenblatt RB, Rosenbaum JT, Levy-Clarke GA, Kempen JH; SITE Cohort Research Group.

Am J Ophthalmol. 2019 Dec;208:68-75. doi: 10.1016/j.ajo.2019.07.008. Epub 2019 Jul 22.

PMID:
31344346
6.

Association of Systemic Inflammation With Retinal Vascular Caliber in Patients With AIDS.

Jabs DA, Van Natta ML, Trang G, Jones N, Milush JM, Cheu R, Klatt NR, Pak JW, Danis RP, Hunt PW.

Invest Ophthalmol Vis Sci. 2019 May 1;60(6):2218-2225. doi: 10.1167/iovs.18-26070.

7.

Relationship Between Opacity of Cytomegalovirus Retinitis Lesion Borders and Severity of Immunodeficiency Among People With AIDS.

Holland GN, Van Natta ML, Goldenberg DT, Ritts R Jr, Danis RP, Jabs DA; Studies of Ocular Complications of AIDS Research Group.

Invest Ophthalmol Vis Sci. 2019 May 1;60(6):1853-1862. doi: 10.1167/iovs.18-26517.

8.

Remission Of Non-Infectious Anterior Scleritis: Incidence And Predictive Factors.

Kempen JH, Pistilli M, Begum H, Fitzgerald TD, Liesegang TL, Payal A, Zebardast N, Bhatt NP, Foster CS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Sen HN, Suhler EB, Thorne JE.

Am J Ophthalmol. 2019 Apr 2. pii: S0002-9394(19)30134-5. doi: 10.1016/j.ajo.2019.03.024. [Epub ahead of print]

PMID:
30951689
9.

RETINAL FINDINGS IN PRESUMED INFECTIOUS POSTERIOR UVEITIS AND CORRELATION WITH POLYMERASE CHAIN REACTION RESULTS.

Elyashiv SM, Samson CM, Jabs DA.

Retina. 2018 Dec 27. doi: 10.1097/IAE.0000000000002423. [Epub ahead of print]

PMID:
30601389
10.

Association of Age-related Macular Degeneration With Mortality in Patients With Acquired Immunodeficiency Syndrome; Role of Systemic Inflammation.

Jabs DA, Van Natta ML, Trang G, Jones NG, Milush JM, Cheu R, Klatt NR, Danis RP, Hunt PW.

Am J Ophthalmol. 2019 Mar;199:230-237. doi: 10.1016/j.ajo.2018.12.002. Epub 2018 Dec 12.

PMID:
30552890
11.

Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema: The PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial.

Thorne JE, Sugar EA, Holbrook JT, Burke AE, Altaweel MM, Vitale AT, Acharya NR, Kempen JH, Jabs DA; Multicenter Uveitis Steroid Treatment Trial Research Group.

Ophthalmology. 2019 Feb;126(2):283-295. doi: 10.1016/j.ophtha.2018.08.021. Epub 2018 Sep 27.

PMID:
30269924
12.

Assessing the Precision of ICD-10 Codes for Uveitis in 2 Electronic Health Record Systems.

Palestine AG, Merrill PT, Saleem SM, Jabs DA, Thorne JE.

JAMA Ophthalmol. 2018 Oct 1;136(10):1186-1190. doi: 10.1001/jamaophthalmol.2018.3001.

13.

Improving the Diagnostic Criteria for Vogt-Koyanagi-Harada Disease.

Jabs DA.

JAMA Ophthalmol. 2018 Sep 1;136(9):1032-1033. doi: 10.1001/jamaophthalmol.2018.2657. No abstract available.

PMID:
29978179
14.

Secular trends in opportunistic infections, cancers and mortality in patients with AIDS during the era of modern combination antiretroviral therapy.

Sezgin E, Van Natta ML, Thorne JE, Puhan MA, Jabs DA; Longitudinal Studies of the Ocular Complications of AIDS (SOCA) Research Group.

HIV Med. 2018 Jul;19(6):411-419. doi: 10.1111/hiv.12609. Epub 2018 Mar 24.

PMID:
29573311
15.

Association of Retinal Vascular Caliber and Age-Related Macular Degeneration in Patients With the Acquired Immunodeficiency Syndrome.

Jabs DA, Van Natta ML, Pak JW, Danis RP, Hunt PW.

Invest Ophthalmol Vis Sci. 2018 Feb 1;59(2):904-908. doi: 10.1167/iovs.17-23334.

16.

Interobserver Agreement Among Uveitis Experts on Uveitic Diagnoses: The Standardization of Uveitis Nomenclature Experience.

Jabs DA, Dick A, Doucette JT, Gupta A, Lightman S, McCluskey P, Okada AA, Palestine AG, Rosenbaum JT, Saleem SM, Thorne J, Trusko B; Standardization of Uveitis Nomenclature Working Group.

Am J Ophthalmol. 2018 Feb;186:19-24. doi: 10.1016/j.ajo.2017.10.028. Epub 2017 Nov 6.

PMID:
29122577
17.

Immunosuppression for the Uveitides.

Jabs DA.

Ophthalmology. 2018 Feb;125(2):193-202. doi: 10.1016/j.ophtha.2017.08.007. Epub 2017 Sep 20. Review.

18.

Insurance status and mortality among patients with AIDS.

Jabs AW, Jabs DA, Van Natta ML, Palella FJ, Meinert CL; Studies of the Ocular Complications of AIDS Research Group.

HIV Med. 2018 Jan;19(1):7-17. doi: 10.1111/hiv.12531. Epub 2017 Jul 11.

19.

Longitudinal Vision-Related Quality of Life for Patients with Noninfectious Uveitis Treated with Fluocinolone Acetonide Implant or Systemic Corticosteroid Therapy.

Sugar EA, Venugopal V, Thorne JE, Frick KD, Holland GN, Wang RC, Almanzor R, Jabs DA, Holbrook JT; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group.

Ophthalmology. 2017 Nov;124(11):1662-1669. doi: 10.1016/j.ophtha.2017.05.015. Epub 2017 Jun 16.

20.

Incidence of Intermediate-stage Age-related Macular Degeneration in Patients With Acquired Immunodeficiency Syndrome.

Jabs DA, Van Natta ML, Pak JW, Danis RP, Hunt PW.

Am J Ophthalmol. 2017 Jul;179:151-158. doi: 10.1016/j.ajo.2017.05.004. Epub 2017 May 10.

21.

Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis.

Writing Committee for the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study Research Group, Kempen JH, Altaweel MM, Holbrook JT, Sugar EA, Thorne JE, Jabs DA.

JAMA. 2017 May 16;317(19):1993-2005. doi: 10.1001/jama.2017.5103.

22.

Risk of Ocular Hypertension in Adults with Noninfectious Uveitis.

Daniel E, Pistilli M, Kothari S, Khachatryan N, Kaçmaz RO, Gangaputra SS, Sen HN, Suhler EB, Thorne JE, Foster CS, Jabs DA, Nussenblatt RB, Rosenbaum JT, Levy-Clarke GA, Bhatt NP, Kempen JH; Systemic Immunosuppressive Therapy for Eye Diseases Research Group.

Ophthalmology. 2017 Aug;124(8):1196-1208. doi: 10.1016/j.ophtha.2017.03.041. Epub 2017 Apr 19.

23.

Cytomegalovirus Retinitis in Patients With Acquired Immunodeficiency Syndrome After Initiating Antiretroviral Therapy.

Jabs DA, Van Natta ML, Holland GN, Danis R; Studies of the Ocular Complications of AIDS Research Group.

Am J Ophthalmol. 2017 Feb;174:23-32. doi: 10.1016/j.ajo.2016.10.011. Epub 2016 Oct 27.

24.

Prevalence of the Uveitides in the United States.

Jabs DA.

JAMA Ophthalmol. 2016 Nov 1;134(11):1245-1246. doi: 10.1001/jamaophthalmol.2016.3289. No abstract available.

PMID:
27607536
25.

Adalimumab for Ocular Inflammation.

Durrani K, Kempen JH, Ying GS, Kacmaz RO, Artornsombudh P, Rosenbaum JT, Suhler EB, Thorne JE, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Foster CS Md Facs, Systemic Immunosuppressive Therapy For Eye Diseases Site Research Group.

Ocul Immunol Inflamm. 2017 Jun;25(3):405-412. doi: 10.3109/09273948.2015.1134581. Epub 2016 Mar 22.

26.

Remission of Intermediate Uveitis: Incidence and Predictive Factors.

Kempen JH, Gewaily DY, Newcomb CW, Liesegang TL, Kaçmaz RO, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Sen HN, Suhler EB, Thorne JE, Foster CS, Jabs DA, Payal A, Fitzgerald TD; Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group.

Am J Ophthalmol. 2016 Apr;164:110-7.e2. doi: 10.1016/j.ajo.2015.12.034. Epub 2016 Jan 6.

27.

Dissociations of the Fluocinolone Acetonide Implant: The Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.

Holbrook JT, Sugar EA, Burke AE, Vitale AT, Thorne JE, Davis JL, Jabs DA; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group.

Am J Ophthalmol. 2016 Apr;164:29-36. doi: 10.1016/j.ajo.2015.12.028. Epub 2015 Dec 31.

28.

Risk of Retinal Neovascularization in Cases of Uveitis.

Patel AK, Newcomb CW, Liesegang TL, Pujari SS, Suhler EB, Thorne JE, Foster CS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Sen HN, Artornsombudh P, Kothari S, Kempen JH; Systemic Immunosuppressive Therapy for Eye Diseases Research Group.

Ophthalmology. 2016 Mar;123(3):646-54. doi: 10.1016/j.ophtha.2015.10.056. Epub 2015 Dec 11.

29.

Treatment Options for Juvenile Idiopathic Arthritis (JIA) Associated Uveitis.

Amin RM, Miserocchi E, Thorne JE, Hornbeak D, Jabs DA, Zierhut M.

Ocul Immunol Inflamm. 2016;24(1):81-90. doi: 10.3109/09273948.2015.1077976. Epub 2015 Dec 11. Review.

PMID:
26652068
30.

Peripheral Cryoablation for Treatment of Active Pars Planitis: Long-Term Outcomes of a Retrospective Study.

Sohn EH, Chaon BC, Jabs DA, Folk JC.

Am J Ophthalmol. 2016 Feb;162:35-42.e2. doi: 10.1016/j.ajo.2015.11.009. Epub 2015 Nov 11.

PMID:
26576712
31.

Cataract Surgery Outcomes in Uveitis: The Multicenter Uveitis Steroid Treatment Trial.

Sen HN, Abreu FM, Louis TA, Sugar EA, Altaweel MM, Elner SG, Holbrook JT, Jabs DA, Kim RY, Kempen JH; Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study Research Group.

Ophthalmology. 2016 Jan;123(1):183-90. doi: 10.1016/j.ophtha.2015.09.022. Epub 2015 Oct 20.

32.

Factors Predicting Visual Acuity Outcome in Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial.

Kempen JH, Van Natta ML, Altaweel MM, Dunn JP, Jabs DA, Lightman SL, Thorne JE, Holbrook JT; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group.

Am J Ophthalmol. 2015 Dec;160(6):1133-1141.e9. doi: 10.1016/j.ajo.2015.09.017. Epub 2015 Sep 18.

33.

Outcome of Treatment of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial 2-Year Results.

Tomkins-Netzer O, Lightman S, Drye L, Kempen J, Holland GN, Rao NA, Stawell RJ, Vitale A, Jabs DA; Multicenter Uveitis Steroid Treatment Trial Research Group.

Ophthalmology. 2015 Nov;122(11):2351-9. doi: 10.1016/j.ophtha.2015.07.036. Epub 2015 Sep 7.

34.

Relationship between Human Immunodeficiency Virus Neuroretinal Disorder and Vision-Specific Quality of Life among People with AIDS.

Ashraf DC, May KP, Holland GN, Van Natta ML, Wu AW, Thorne JE, Jabs DA; Studies of the Ocular Complications of AIDS Research Group.

Ophthalmology. 2015 Dec;122(12):2560-7. doi: 10.1016/j.ophtha.2015.07.037. Epub 2015 Sep 6.

35.

Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.

Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Kempen JH, Altaweel MM, Drye LT, Holbrook JT, Jabs DA, Sugar EA, Thorne JE.

Ophthalmology. 2015 Oct;122(10):1967-75. doi: 10.1016/j.ophtha.2015.06.042. Epub 2015 Aug 20.

36.

The Risk of Intraocular Pressure Elevation in Pediatric Noninfectious Uveitis.

Kothari S, Foster CS, Pistilli M, Liesegang TL, Daniel E, Sen HN, Suhler EB, Thorne JE, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Lawrence SD, Kempen JH; Systemic Immunosuppressive Therapy for Eye Diseases Research Group.

Ophthalmology. 2015 Oct;122(10):1987-2001. doi: 10.1016/j.ophtha.2015.06.041. Epub 2015 Jul 30.

37.

Multimodal Imaging of a Tuberculous Granuloma.

Goldberg NR, Jabs DA.

Retina. 2015 Sep;35(9):1919-20. doi: 10.1097/IAE.0000000000000543. No abstract available.

PMID:
25932546
38.

Long-term Outcomes of Cytomegalovirus Retinitis in the Era of Modern Antiretroviral Therapy: Results from a United States Cohort.

Jabs DA, Ahuja A, Van Natta ML, Lyon AT, Yeh S, Danis R; Studies of the Ocular Complications of AIDS Research Group.

Ophthalmology. 2015 Jul;122(7):1452-63. doi: 10.1016/j.ophtha.2015.02.033. Epub 2015 Apr 17.

39.

Prevalence of intermediate-stage age-related macular degeneration in patients with acquired immunodeficiency syndrome.

Jabs DA, Van Natta ML, Sezgin E, Pak JW, Danis R; Studies of the Ocular Complications of AIDS Research Group.

Am J Ophthalmol. 2015 Jun;159(6):1115-1122.e1. doi: 10.1016/j.ajo.2015.01.037. Epub 2015 Mar 11.

40.

Incidence and long-term outcomes of the human immunodefıciency virus neuroretinal disorder in patients with AIDS.

Jabs DA, Drye L, Van Natta ML, Thorne JE, Holland GN; Studies of the Ocular Complications of AIDS Research Group.

Ophthalmology. 2015 Apr;122(4):760-8. doi: 10.1016/j.ophtha.2014.11.009. Epub 2015 Jan 16.

41.

GWATCH: a web platform for automated gene association discovery analysis.

Svitin A, Malov S, Cherkasov N, Geerts P, Rotkevich M, Dobrynin P, Shevchenko A, Guan L, Troyer J, Hendrickson S, Dilks HH, Oleksyk TK, Donfield S, Gomperts E, Jabs DA, Sezgin E, Van Natta M, Harrigan PR, Brumme ZL, O'Brien SJ.

Gigascience. 2014 Nov 5;3:18. doi: 10.1186/2047-217X-3-18. eCollection 2014.

42.

Optical Coherence Tomography Imaging of Presumed Sarcoid Retinal and Optic Nerve Nodules.

Goldberg NR, Jabs DA, Busingye J.

Ocul Immunol Inflamm. 2016 Jun;24(3):293-6. doi: 10.3109/09273948.2014.971972. Epub 2014 Oct 30.

PMID:
25356670
43.

Success with single-agent immunosuppression for multifocal choroidopathies.

Goldberg NR, Lyu T, Moshier E, Godbold J, Jabs DA.

Am J Ophthalmol. 2014 Dec;158(6):1310-7. doi: 10.1016/j.ajo.2014.08.039. Epub 2014 Sep 3.

44.

Risk of cataract among subjects with acquired immune deficiency syndrome free of ocular opportunistic infections.

Kempen JH, Sugar EA, Varma R, Dunn JP, Heinemann MH, Jabs DA, Lyon AT, Lewis RA; Studies of Ocular Complications of AIDS Research Group.

Ophthalmology. 2014 Dec;121(12):2317-24. doi: 10.1016/j.ophtha.2014.06.014. Epub 2014 Aug 8.

45.

Periocular corticosteroid injections in uveitis: effects and complications.

Sen HN, Vitale S, Gangaputra SS, Nussenblatt RB, Liesegang TL, Levy-Clarke GA, Rosenbaum JT, Suhler EB, Thorne JE, Foster CS, Jabs DA, Kempen JH.

Ophthalmology. 2014 Nov;121(11):2275-86. doi: 10.1016/j.ophtha.2014.05.021. Epub 2014 Jul 11.

46.

Author reply: To PMID 24359625.

Read RW, Levy-Clarke G, Jabs DA, Rosenbaum JT, Vitale A, Van Gelder RN.

Ophthalmology. 2014 Oct;121(10):e58-9. doi: 10.1016/j.ophtha.2014.05.034. Epub 2014 Jul 9. No abstract available.

PMID:
25015217
47.

Cost-effectiveness of fluocinolone acetonide implant versus systemic therapy for noninfectious intermediate, posterior, and panuveitis.

Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Sugar EA, Holbrook JT, Kempen JH, Burke AE, Drye LT, Thorne JE, Louis TA, Jabs DA, Altaweel MM, Frick KD.

Ophthalmology. 2014 Oct;121(10):1855-62. doi: 10.1016/j.ophtha.2014.04.022. Epub 2014 Jun 5.

48.

Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection.

Hunt PW, Sinclair E, Rodriguez B, Shive C, Clagett B, Funderburg N, Robinson J, Huang Y, Epling L, Martin JN, Deeks SG, Meinert CL, Van Natta ML, Jabs DA, Lederman MM.

J Infect Dis. 2014 Oct 15;210(8):1228-38. doi: 10.1093/infdis/jiu238. Epub 2014 Apr 21.

49.

Epiretinal membranes in uveitic macular edema: effect on vision and response to therapy.

Lehpamer B, Moshier E, Pahk P, Goldberg N, Ackert J, Godbold J, Jabs DA.

Am J Ophthalmol. 2014 May;157(5):1048-55. doi: 10.1016/j.ajo.2014.01.020. Epub 2014 Jan 30.

50.

Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.

Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN.

Ophthalmology. 2014 Mar;121(3):785-96.e3. doi: 10.1016/j.ophtha.2013.09.048. Epub 2013 Dec 17.

PMID:
24359625

Supplemental Content

Support Center